First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
Open accessAbstract
The European Respiratory Journal has recently discussed delamanid and bedaquiline and their use in difficult-to-treat cases affected by multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant (XDR-TB) [1–4]. The use of delamanid or bedaquiline is particularly important when four active drugs cannot be identified and included in a regimen, as per World Health Organization (WHO) guidelines [1–6]. Recently a debate has been initiated around the report of a severe, almost untreatable, XDR-TB case who could not access both new drugs simultaneously [7–10] due to concerns about possible additive toxicity (cardiotoxicity), as well as the lack of evidence and specific guidance on their combined use [10–13]. Report of the first case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Delamanid and bedaquiline have shown promise to fight against MDR TB.
“Delamanid and bedaquiline have shown promise to fight against multidrug resistance (MDR) TB.200”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 13 · Cited by 92
Research works printed but not linked: 2
- [11]World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB2014.23. Geneva, World Health Organization, 2014. 26110189
- [12]World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013. 23967502
- Authors
- Tadolini, M., Lingtsang, R. D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T. D., Centis, R., & Migliori, G. B.
- Affiliations
- University of Bologna (IT)
- Tibetan Delek Hospital (IN)
- Barts Health NHS Trust (GB)
- Fondazione Salvatore Maugeri (IT)
- Corresponding author
- Migliori, Giovanni Battista
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2016-06-10
- Volume
- 48
- Issue
- 3
- Pages
- 935-938
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC5007220
- OpenAlex
- W2417230716
- Cited by
- 92
- References
- 13
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 24 · 2017: 20 · 2016: 17
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Keywords
- extensively drug-resistant tuberculosis, delamanid, bedaquiline, combination therapy, multidrug-resistant tuberculosis, treatment toxicity, cardiotoxicity, drug-resistant tuberculosis treatment
- MeSH terms
- Adult, Antitubercular Agents, Female, Humans, Nitroimidazoles, Oxazoles, Extensively Drug-Resistant Tuberculosis, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
